Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 7/20 | 0.65 |
| ▸ | BACE1 | P56817 | 7/20 | 0.65 |
| ▸ | BCHE | P06276 | 6/20 | 0.65 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.55 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.51 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.50 |
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.50 |
| ▸ | PHGDH | O43175 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.48 |
| ▸ | HTR5A | P47898 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | DRD4 | P21917 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13989041 | 0.90 | ACHE (0.53) | ACHEBACE1BCHETEAD1SLC6A5 | |
| SCHEMBL4838899 | 0.86 | BCHE (0.61) | ACHEBACE1BCHETEAD1SLC6A5 | |
| SCHEMBL3456800 | 0.85 | HRH3 (0.54) | ACHEBACE1BCHECARM1PRMT6 | |
| SCHEMBL3456633 | 0.84 | ACHE (0.59) | ACHEBACE1BCHETEAD1SLC6A5 | |
| SCHEMBL6390812 | 0.84 | ACHE (0.59) | ACHEBACE1BCHETEAD1CARM1 | |
| SCHEMBL3457662 | 0.83 | BCHE (0.57) | ACHEBACE1BCHETEAD1CARM1 | |
| SCHEMBL3457686 | 0.82 | ACHE (0.64) | ACHEBACE1BCHECARM1PRMT6 | |
| SCHEMBL3456523 | 0.82 | SLC2A1 (0.55) | ACHEBACE1BCHESLC6A5HRH3 | |
| SCHEMBL3456943 | 0.82 | BCHE (0.54) | ACHEBACE1BCHETEAD1SLC6A5 | |
| SCHEMBL4208525 | 0.82 | ACHE (0.65) | ACHEBACE1BCHETEAD1SLC6A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9266841-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2016-02-23 | — | — | US | disclosed |
| US-20150045375-A1 | NOVEL COMPOUNDS | GLAXO GROUP LTD (GB) | 2015-02-12 | — | — | US | disclosed |
| US-8871775-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2014-10-28 | — | — | US | disclosed |
| EP-2258688-B1 | Pyridinone derivatives for treatment of atherosclerosis | SMITHKLINE BEECHAM LTD (GB) | 2012-11-21 | — | — | EP | disclosed |
| US-20120172378-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2012-07-05 | — | — | US | disclosed |
| EP-2258688-A1 | Pyridinone derivatives for treatment of atherosclerosis | SmithKline Beecham Limited (GB) | 2010-12-08 | — | — | EP | disclosed |
| US-20100144765-A1 | 5,6-TRIMETHYLENEPYRIMIDIN-4-ONE COMPOUNDS | HICKEY DEIDRE MARY BERNADETTE | 2010-06-10 | — | — | US | disclosed |
| US-20100144765-A1 | 5,6-TRIMETHYLENEPYRIMIDIN-4-ONE COMPOUNDS | HICKEY DEIDRE MARY BERNADETTE | 2010-06-10 | — | — | US | disclosed |
| US-7652019-B2 | Treating atherosclerosis by administering 1-(N-(2-(diethylamino)ethyl)-N-(4-(4-trifluoromethylphenyl)benzyl)aminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5,6-trimethylenepyrimidin-4-one or a salt; coadministering an antioxidant probucol; inhibitor of platlet activating factor acetylhydrolase | SMITHKLINE BEECHAM PLC (GB) | 2010-01-26 | — | — | US | disclosed |
| US-7652019-B2 | Treating atherosclerosis by administering 1-(N-(2-(diethylamino)ethyl)-N-(4-(4-trifluoromethylphenyl)benzyl)aminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5,6-trimethylenepyrimidin-4-one or a salt; coadministering an antioxidant probucol; inhibitor of platlet activating factor acetylhydrolase | SMITHKLINE BEECHAM PLC (GB) | 2010-01-26 | — | — | US | disclosed |
| US-7169924-B2 | Pyrimidinone derivatives and their use in the treatment of atherosclerosis | SMITHKLINE BEECHAM PLC (GB) | 2007-01-30 | — | — | US | disclosed |
| US-20060241126-A1 | Pyrimidinone Derivatives and Their Use in the Treatment of Atherosclerosis | ELLIOTT RICHARD L | 2006-10-26 | — | — | US | disclosed |
| EP-1644353-A1 | AMIDE-SUBSTITUTED 1,2,4-TRIAZIN-5(2H)-ONES FOR THE TREATMENT OF CHRONICALLY INFLAMMATORY DISEASES | Bayer HealthCare AG (DE) | 2006-04-12 | — | — | EP | disclosed |
| US-20050020832-A1 | Pyridone, pyridazone and triazone derivatives as lp-pla2 inhibitors | SMITHKLINE BEECHAM PLC (GB) | 2005-01-27 | — | — | US | disclosed |
| US-20050014793-A1 | Pyridinone derivatives for treatment of atherosclerosis | GLAXO GROUP LIMITED (GB) | 2005-01-20 | — | — | US | disclosed |
| WO-2005003118-A1 | AMIDE-SUBSTITUTED 1,2,4-TRIAZIN-5(2H)-ONES FOR THE TREATMENT OF CHRONICALLY INFLAMMATORY DISEASES | BAYER HEALTHCARE AG (DE) | 2005-01-13 | — | — | WO | disclosed |
| EP-1337517-A1 | PYRIMIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF ATHEROSCLEROSIS | SMITHKLINE BEECHAM PLC (GB) | 2003-08-27 | — | — | EP | disclosed |
| EP-1326841-A1 | PYRIDINONE DERIVATIVES FOR TREATMENT OF ATHEROSCLEROSIS | SmithKline Beecham P.L.C. (GB) | 2003-07-16 | — | — | EP | disclosed |
| WO-2002030904-A1 | PYRIDINONE DERIVATIVES FOR TREATMENT OF ATHEROSCLEROSIS | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-04-18 | — | — | WO | disclosed |
| WO-2002030911-A1 | PYRIMIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF ATHEROSCLEROSIS | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014793-A1 | Pyridinone derivatives for treatment of atherosclerosis | PNPO, PLA2G7, PLA2G4B | ACHE 1388/4885BACE1 1428/4885BCHE 2168/4885 |
| US-20050020832-A1 | Pyridone, pyridazone and triazone derivatives as lp-pla2 inhibitors | PLPBP, PLA2G4B, PLA2G12B | ACHE 1792/4885BACE1 1728/4885BCHE 3333/4885 |
| US-20150045375-A1 | NOVEL COMPOUNDS | PLA2G7, ALOX15B, PLA2G1B | ACHE 3682/4885BACE1 689/4885BCHE 3706/4885 |
| US-20120172378-A1 | NOVEL COMPOUNDS | PLA2G7, ALOX15B, PLA2G1B | ACHE 3682/4885BACE1 689/4885BCHE 3706/4885 |
| US-20100144765-A1 | 5,6-TRIMETHYLENEPYRIMIDIN-4-ONE COMPOUNDS | PLA2G4A, PLA2G4B, PLA2G1B | ACHE 1946/4885BACE1 421/4885BCHE 3003/4885 |
| US-20060241126-A1 | Pyrimidinone Derivatives and Their Use in the Treatment of Atherosclerosis | PLA2G7, PLA2G1B, PLA2G4B | ACHE 2707/4885BACE1 786/4885BCHE 2358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.